Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine in Overactive Bladder Syndrome
NCT00220363Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2004
- Primary completion
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fesoterodine in overactive bladder syndrome (OAB) (4 arms), sponsored by Pfizer. Primary endpoints: Change in the average number of micturitions per 24 hours at 12 weeks, Change in the average number of urge incontinence episodes per 24 hours at 12 weeks and 1 more. Started Jan 2004; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT00220363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220363.